Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00120393 · ClinicalTrials.gov registry record · Phase 3
Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir
A Phase 3 study of HIV Infections, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 192
- Enrollment target
- 14
- Study locations
NCT00120393 is a Phase 3 study of HIV Infections that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 192 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (57% lower). The trial reports 14 study locations across 12 states.
The verdict
NCT00120393, a Phase 3 study of HIV Infections, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 192 participants
- Enrollment target
- 14
- Study locations
Study Summary
Patients with HIV who are virologically suppressed on a lopinavir/ritonavir combination highly active antiretroviral therapy (HAART) regimen but with elevated non-HDL cholesterol are randomized to remain on lopinavir/ritonavir or change to atazanavir/ritonavir in combination with current nucleoside reverse transcriptase inhibitors (NRTIs).
Conditions Studied
Interventions
- DRUG atazanavir/ritonavir +2 NRTIs (immediate Switch Group)
- DRUG LPV/r +2 NRTIs (Delayed/optional Switch Group)
Study Locations (14)
California
- Local Institution - Bakersfield
- Local Institution - Los Angeles
- Local Institution - San Francisco
Arizona
- Local Institution - Phoenix
Florida
- Local Institution - Miami
Massachusetts
- Local Institution - Boston
New York
- Local Institution - New York
Ohio
- Local Institution - Cincinnati
Oregon
- Local Institution - Portland
Pennsylvania
- Local Institution - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2004-01 |
| Est. Completion | 2006-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00120393
The ClinicalTrials.gov registry entry for NCT00120393 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (57% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which atazanavir/ritonavir +2 NRTIs (immediate Switch Group) is the first listed.
NCT00120393 reports 14 study locations spanning 12 distinct geographic areas - top geographies include California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT00120393 about?
NCT00120393 is a clinical study titled "Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir". Patients with HIV who are virologically suppressed on a lopinavir/ritonavir combination highly active antiretroviral therapy (HAART) regimen but with elevated non-HDL cholesterol are randomized to remain on lopinavir/ritonavir or change to atazanavir/ritonavir in combination with current nucleoside ...
What is the current status of trial NCT00120393?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 192 participants. The study started on 2004-01. Estimated completion is 2006-05.
What conditions does trial NCT00120393 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00120393?
The interventions under investigation include: atazanavir/ritonavir +2 NRTIs (immediate Switch Group) (DRUG), LPV/r +2 NRTIs (Delayed/optional Switch Group) (DRUG).
Who is sponsoring clinical trial NCT00120393?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00120393 being conducted?
This trial has 14 study locations across Arizona, California, Florida, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
RECRUITING · Phase 3
-
Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention
RECRUITING · Phase 3
-
SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder
RECRUITING · Phase 3
-
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
ACTIVE NOT RECRUITING · Phase 3
-
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.